$NSPR
InspireMD, Inc. Stock $nspr

$nspr Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223027060 Filed on August 07, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$1.556M	$1.649M	$1.531M
YoY Change	8.74%	7.71%	47.5%
Cost Of Revenue	$1.118M	$1.158M	$1.100M
YoY Change	4.98%	5.27%	41.75%
Gross Profit	$438.0K	$491.0K	$431.0K
YoY Change	19.67%	13.92%	64.5%
Gross Profit Margin	28.15%	29.78%	28.15%
Selling, General & Admin	$3.967M	$3.813M	$3.056M
YoY Change	36.09%	24.77%	26.7%
% of Gross Profit	905.71%	776.58%	709.05%
Research & Development	$2.110M	$1.993M	$2.056M
YoY Change	2.38%	-3.06%	59.38%
% of Gross Profit	481.74%	405.91%	477.03%
Depreciation & Amortization	$61.00K	$58.00K	$43.00K
YoY Change	22.0%	34.88%	30.3%
% of Gross Profit	13.93%	11.81%	9.98%
Operating Expenses	$6.077M	$5.806M	$5.112M
YoY Change	22.13%	13.58%	38.09%
Operating Profit	-$5.639M	-$5.315M	-$4.681M
YoY Change	22.32%	13.54%	36.08%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$461.0K	$238.0K	$45.00K
YoY Change	469.14%	428.89%	-167.16%
Pretax Income	-$5.178M	-$5.077M	-$4.636M
YoY Change	14.33%	9.51%	32.19%
Income Tax
% Of Pretax Income
Net Earnings	-$5.178M	-$5.077M	-$4.636M
YoY Change	14.33%	9.51%	32.19%
Net Earnings / Revenue	-332.78%	-307.88%	-302.81%
Basic Earnings Per Share	-$0.15	-$0.24	-$0.59
Diluted Earnings Per Share	-$0.15	-$0.24	-$593.8K
COMMON SHARES
Basic Shares Outstanding	21.20M shares	8.356M shares	7.808M shares
Diluted Shares Outstanding	33.98M shares	21.07M shares	7.808M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$43.00M	$46.99M	$26.47M
YoY Change	104.31%	77.53%	-36.09%
Cash & Equivalents	$13.84M	$11.55M	$6.393M
Short-Term Investments	$29.16M	$35.45M	$20.08M
Other Short-Term Assets	$476.0K	$56.00K	$221.0K
YoY Change	-44.65%	-74.66%	250.79%
Inventory	$1.846M	$1.689M	$1.454M
Prepaid Expenses	$476.0K	$56.00K	$221.0K
Receivables	$1.045M	$1.470M	$1.183M
Other Receivables	$363.0K	$312.0K	$171.0K
Total Short-Term Assets	$46.73M	$50.52M	$29.50M
YoY Change	89.24%	71.25%	-32.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$907.0K	$2.261M	$700.0K
YoY Change	3.54%	223.0%	-58.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$847.0K	$857.0K	$849.0K
YoY Change	-1.28%	0.94%	11.86%
Total Long-Term Assets	$3.292M	$3.118M	$3.266M
YoY Change	-2.29%	-4.53%	33.14%
TOTAL ASSETS
Total Short-Term Assets	$46.73M	$50.52M	$29.50M
Total Long-Term Assets	$3.292M	$3.118M	$3.266M
Total Assets	$50.02M	$53.64M	$32.77M
YoY Change	78.25%	63.7%	-29.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$600.0K	$4.829M	$1.127M
YoY Change	48.51%	328.48%	52.5%
Accrued Expenses	$926.0K	$742.0K	$1.563M
YoY Change	-35.02%	-52.53%	-44.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.690M	$4.829M	$4.712M
YoY Change	18.4%	2.48%	28.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.073M	$1.996M	$2.312M
YoY Change	-7.04%	-13.67%	23.9%
Total Long-Term Liabilities	$2.073M	$1.996M	$2.312M
YoY Change	-7.04%	-13.67%	23.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.690M	$4.829M	$4.712M
Total Long-Term Liabilities	$2.073M	$1.996M	$2.312M
Total Liabilities	$6.763M	$6.825M	$7.024M
YoY Change	9.24%	-2.83%	26.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$216.1M	-$210.9M	-$192.2M
YoY Change	9.84%	9.73%
Common Stock	$2.000K	$2.000K	$1.000K
YoY Change	100.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$43.26M	$46.81M	$25.74M
YoY Change
Total Liabilities & Shareholders Equity	$50.02M	$53.64M	$32.77M
YoY Change	78.25%	63.7%	-29.35%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$5.178M	-$5.077M	-$4.636M
YoY Change	14.33%	9.51%	32.19%
Depreciation, Depletion And Amortization	$61.00K	$58.00K	$43.00K
YoY Change	22.0%	34.88%	30.3%
Cash From Operating Activities	-$4.039M	-$3.325M	-$3.091M
YoY Change	-20.87%	7.57%	22.27%
INVESTING ACTIVITIES
Capital Expenditures	$96.00K	$45.00K	-$115.0K
YoY Change	-142.48%	-139.13%	112.96%
Acquisitions
YoY Change
Other Investing Activities	$6.480M	-$26.85M	$1.963M
YoY Change	117.45%	-1467.6%	-5552.78%
Cash From Investing Activities	$6.384M	-$26.89M	$1.848M
YoY Change	131.81%	-1555.14%	-2153.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.000K	37.53M	-37.00K
YoY Change	-103.88%	-101543.24%	-3800.0%
NET CHANGE
Cash From Operating Activities	-4.039M	-3.325M	-3.091M
Cash From Investing Activities	6.384M	-26.89M	1.848M
Cash From Financing Activities	4.000K	37.53M	-37.00K
Net Change In Cash	2.349M	7.318M	-1.280M
YoY Change	-195.76%	-671.72%	-51.09%
FREE CASH FLOW
Cash From Operating Activities	-$4.039M	-$3.325M	-$3.091M
Capital Expenditures	$96.00K	$45.00K	-$115.0K
Free Cash Flow	-$4.135M	-$3.370M	-$2.976M
YoY Change	-15.23%	13.24%	20.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001433607
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	NSPR	Changes In Fair Value Of Marketable Securities ChangesInFairValueOfMarketableSecurities		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
	NSPR	Issuance Costs Of At Market Offering IssuanceCostsOfAtMarketOffering		usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		usd
	NSPR	Noncash Acquisition Of Right Of Use Assets By Means Of Lease Liabilities NoncashAcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities		usd
CY2022Q4	NSPR	Marketable Securities Maturities Within One Year Fair Value MarketableSecuritiesMaturitiesWithinOneYearFairValue		usd
CY2022Q4	NSPR	Marketable Securities Maturities After One Through Two Years Fair Value MarketableSecuritiesMaturitiesAfterOneThroughTwoYearsFairValue		usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35731
	dei	Entity Registrant Name EntityRegistrantName	InspireMD, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2123838
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4 Menorat Hamaor St.
	dei	Entity Address City Or Town EntityAddressCityOrTown	Tel Aviv
	dei	Entity Address Country EntityAddressCountry	IL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	6744832
	dei	City Area Code CityAreaCode	888
	dei	Local Phone Number LocalPhoneNumber	776-6204
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	NSPR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21195103	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11545000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4632000	usd
CY2023Q2	NSPR	Shortterm Bank Deposits ShorttermBankDeposits	6631000	usd
CY2022Q4	NSPR	Shortterm Bank Deposits ShorttermBankDeposits	13171000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	28817000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1470000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1034000	usd
CY2023Q2	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	312000	usd
CY2022Q4	us-gaap	Nontrade Receivables Current NontradeReceivablesCurrent	213000	usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	56000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	655000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1689000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1621000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	50520000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	21326000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	873000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	917000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1388000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1554000	usd
CY2023Q2	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	857000	usd
CY2022Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	856000	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	3118000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	3327000	usd
CY2023Q2	us-gaap	Assets Assets	53638000	usd
CY2022Q4	us-gaap	Assets Assets	24653000	usd
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	768000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	659000	usd
CY2023Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	4061000	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	4411000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4829000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5070000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	970000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1195000	usd
CY2023Q2	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	1026000	usd
CY2022Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	995000	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1996000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2190000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	6825000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7260000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21192204	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21192204	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8330918	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8330918	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	257729000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9333000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9117000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	218977000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-210918000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-201585000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	46813000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17393000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53638000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24653000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1649000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1531000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2888000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2714000	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1158000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1100000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2024000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2161000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	491000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	431000	usd
	us-gaap	Gross Profit GrossProfit	864000	usd
	us-gaap	Gross Profit GrossProfit	553000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1993000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2056000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3836000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3736000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	892000	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	986000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1680000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1732000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2921000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2070000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5044000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4252000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	5806000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	5112000	usd
	us-gaap	Operating Expenses OperatingExpenses	10560000	usd
	us-gaap	Operating Expenses OperatingExpenses	9720000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5315000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4681000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9696000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9167000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	238000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	45000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	363000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	50000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5077000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4636000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.17
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.59
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.59
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.64
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.17
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.17
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21074187	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21074187	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7807795	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7807795	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14619622	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14619622	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7806030	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7806030	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21074187	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21074187	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7807795	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7807795	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14619622	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14619622	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7806030	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7806030	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	33532000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9117000	usd
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	4563	shares
	NSPR	Sharebased Compensation Related To Restricted Stock And Stock Options Award Net Of Forfeitures Of Shares SharebasedCompensationRelatedToRestrictedStockAndStockOptionsAwardNetOfForfeituresOfShares	1327000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	25742000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	29704000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-4636000	usd
CY2022Q2	NSPR	Sharebased Compensation Related To Stock Restricted Stock Restricted Stock Units And Stock Options Award Shares SharebasedCompensationRelatedToStockRestrictedStockRestrictedStockUnitsAndStockOptionsAwardShares	674000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	25742000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	17393000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9333000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4635000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37534000	usd
	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	4270	shares
	NSPR	Sharebased Compensation Related To Stock Restricted Stock Restricted Stock Units And Stock Options Award Shares SharebasedCompensationRelatedToStockRestrictedStockRestrictedStockUnitsAndStockOptionsAwardShares	1219000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	46813000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	13426000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	13426000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5077000	usd
CY2023Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4635000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	37534000	usd
CY2023Q2	NSPR	Sharebased Compensation Related To Stock Restricted Stock Restricted Stock Units And Stock Options Award Shares SharebasedCompensationRelatedToStockRestrictedStockRestrictedStockUnitsAndStockOptionsAwardShares	930000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	46813000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	46813000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9333000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9117000	usd
	us-gaap	Depreciation Depreciation	113000	usd
	us-gaap	Depreciation Depreciation	84000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	8000	usd
	us-gaap	Defined Benefit Plan Settlements Benefit Obligation DefinedBenefitPlanSettlementsBenefitObligation	42000	usd
	us-gaap	Defined Benefit Plan Settlements Benefit Obligation DefinedBenefitPlanSettlementsBenefitObligation	103000	usd
	NSPR	Changes In Fair Value Of Marketable Securities ChangesInFairValueOfMarketableSecurities	-21000	usd
	NSPR	Loss Gains On Amounts Funded In Respect Of Employee Rights Upon Retirement Net LossGainsOnAmountsFundedInRespectOfEmployeeRightsUponRetirementNet	31000	usd
	NSPR	Loss Gains On Amounts Funded In Respect Of Employee Rights Upon Retirement Net LossGainsOnAmountsFundedInRespectOfEmployeeRightsUponRetirementNet	-90000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-23000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-132000	usd
	NSPR	Change In Right Of Use Asset And Leasing Liability ChangeInRightOfUseAssetAndLeasingLiability	60000	usd
	NSPR	Change In Right Of Use Asset And Leasing Liability ChangeInRightOfUseAssetAndLeasingLiability	63000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1219000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1327000	usd
	NSPR	Interest Income From Shortterm Bank Deposits InterestIncomeFromShorttermBankDeposits	-40000	usd
	NSPR	Interest Income From Shortterm Bank Deposits InterestIncomeFromShorttermBankDeposits	42000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-599000	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-338000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	436000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-41000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	99000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	6000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	68000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	311000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	109000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	234000	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-349000	usd
	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	127000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8156000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7243000	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	5500000	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	10000000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	152000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	9000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	28838000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	12000000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	12000000	usd
	NSPR	Amounts Withdrawn In Respect Of Employee Rights Upon Retirement Net AmountsWithdrawnInRespectOfEmployeeRightsUponRetirementNet	43000	usd
	NSPR	Amounts Withdrawn In Respect Of Employee Rights Upon Retirement Net AmountsWithdrawnInRespectOfEmployeeRightsUponRetirementNet	47000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22442000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1801000	usd
	NSPR	Issuance Costs Of At Market Offering IssuanceCostsOfAtMarketOffering	37000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4635000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	37534000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37534000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-37000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-23000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-132000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6913000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5611000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4632000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12004000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11545000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6393000	usd
	NSPR	Noncash Acquisition Of Right Of Use Assets By Means Of Lease Liabilities NoncashAcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities	835000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_800_eus-gaap--NatureOfOperations_zD3uBOD48GIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_827_zayvpj0gdghd">DESCRIPTION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s MGuard™ Prime™ embolic protection system (“MGuard Prime EPS”) was marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions, or bypass surgery. MGuard Prime EPS combines MicroNet with a bare-metal cobalt-chromium based stent. MGuard Prime EPS received CE mark approval in the European Union in October 2010 for improving luminal diameter and providing embolic protection. Over the past years, there has been a shift in industry preferences away from bare-metal stents, such as MGuard Prime EPS in ST-Elevation Myocardial Infarction (“STEMI”) patients. As a result of declining sales of the MGuard Prime EPS, which the Company believes is largely driven by the predominant industry preferences favoring drug-eluting, or drug-coated, stents, during the second quarter of 2022, the Company ceased sales of the Company’s MGuard Prime EPS following a phase out period.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company markets its products through distributors in international markets, mainly in Europe.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date of issuance of the consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, the Company expects to continue incurring losses and negative cash flows from operations until its product, CGuard™ EPS, reaches commercial profitability. Therefore, in order to fund the Company’s operations until such time that the Company can generate substantial revenues, the Company may need to raise additional funds.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Failure to satisfy regulatory requirements of the new European Medical Device Regulation could prevent the Company from marketing CGuard EPS in countries requiring the CE Mark.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the European Union nations, medical devices must obtain a CE mark before they may be placed on the market. In order to obtain and maintain the CE mark, the Company must Company with EU law on medical devices, which, until May 26, 2021 was governed by the MDD, by presenting comprehensive technical files for the Company’s products demonstrating safety and efficacy of the product to be placed on the market and passing initial and annual quality management system audit as per ISO 13485 standard by a European Notified Body. The company has obtained ISO 13485 quality system certification and CGuard EPS that the Company currently distribute into the European Union, displays the required CE mark. In order to maintain certification, the Company is required to pass an annual surveillance audit conducted by Notified Body auditors. The European Union replaced the MDD with the new MDR regulations. The MDR entered into force after a transitional period of three years and a one year extension of that transition period due to the COVID-19 pandemic on May 26, 2021 and which changes several aspects of the regulatory framework in the European Union. Manufacturers had the duration of the transition period to update their technical documentation and processes to meet the new requirements in order to obtain a CE Mark. In the Company’s specific case, the Company’s CE mark for CGuard EPS under the MDD expired on November 12, 2022, and the Company is in the final stages of technical documentation review by the Notified Body auditor to meet the MDR requirements for recertification. In the meantime, on February 14, 2023, the Company received a derogation per Article 97 paragraph 1 of Regulation 2017/745 from the Agency for Medicines and Health Products (FAMHP) allowing the Company to continue marketing CGuard EPS in the EU until August 15, 2023, subject to certain procedural requirements. Subsequently, on March 20, 2023 Regulation (EU) 2023/607 was published allowing the Company to continue marketing CGuard EPS in EU countries under the MDD directive until December 31, 2027. As a result of the foregoing, the Company may market and sell CGuard EPS in the EU and certain other jurisdictions subject to certain procedural requirements while the Company’s MDR CE recertification is pending.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>c. Risks Related to the Geopolitical and Military Tensions Between Russia and Ukraine in Europe</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, Russia launched a military invasion into Ukraine. The Company derived approximately 12.1% of total sales in Russia and Belarus in 2022 while during the six and three months ended June 30, 2023, the Company’s sales to Russia and Belarus were 10.0% and 11.6%, compared to 6.8% and 10.9% in the six and three months ended June 30, 2022, respectively. The escalation of geopolitical instability in Russia and Ukraine as well as currency fluctuations in the Russian Ruble could negatively impact the Company’s operations, sales, and future growth prospects in that region.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result of the crisis in Ukraine, the United States and the EU have implemented sanctions against certain Russian individuals and entities and have made it more difficult for the Company to collect on outstanding accounts receivable from customers in this region. The Company’s global operations expose the Company to risks that could adversely affect the Company’s business, financial condition, results of operations, cash flows or the market price of the Company’s securities, including the potential for increased tensions between the United States and Russia resulting from the current situation involving Russia and Ukraine, tariffs, economic sanctions and import-export restrictions imposed by either nation, and retaliatory actions by the other nation, as well as the potential negative impact on the Company’s business and sales in Russia and Belarus. Current geopolitical instability in Russia and Ukraine and related sanctions by the U.S. government against certain companies and individuals may hinder the Company’s ability to conduct business with potential or existing customers and vendors in these countries.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S. government has imposed sanctions through several executive orders restricting U.S. companies from conducting business with specified Russian individuals and companies. While the Company believes that the executive orders currently do not preclude the Company from conducting business with the Company’s current customers or vendors in Russia and Belarus, the sanctions imposed by the U.S. government may be expanded in the future to restrict the Company from engaging with them. If the Company is unable to conduct business with new or existing customers or vendors or pursue business opportunities in Russia or Belarus, the Company’s business, including revenue, profitability and cash flows, and operations could be adversely affected. The Company cannot provide assurance that current sanctions or potential future changes in sanctions will not have a material impact on the Company’s operations in Russia and Belarus or on the Company’s financial results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_808_eus-gaap--BasisOfAccounting_zYAc3R3KEZui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - <span id="xdx_82B_z9N12ud9bSla">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -12pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements for the year ended December 31, 2022. In the opinion of the company, all adjustments considered necessary for a fair statement of the results of the interim periods reported herein have been included (consisting only of normal recurring adjustments). These consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2022, as found in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 30, 2023. The results of operations for the three and six months ended June 30, 2023, are not necessarily indicative of results that could be expected for the entire fiscal year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 32.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_84C_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zQ6bpWVfpIr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 32.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zQHzjdbzHUtb">Cash and Cash Equivalents</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 32.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. As of June 30, 2023, cash and cash equivalents consisted of cash, short-term deposits (up to three months from the date of deposit) and money market funds. As of December 31, 2022, this balance consisted solely of cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--MarketableSecuritiesPolicy_zPRfdRbe5HX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 32.75pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zP4VoMjeoBcb">Marketable securities</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable securities consist of debt securities. The Company elected the fair value option to measure and recognize its investments in debt securities in accordance with ASC 825, Financial Instruments as the Company manages its portfolio and evaluates the performance on a fair value basis. Changes in fair value, realized gains and losses on sales of marketable securities, are reflected in the statements of operation as finance expense (income), net.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Securities Borrowed Fair Value Disclosure SecuritiesBorrowedFairValueDisclosure	28838000	usd
CY2023Q2	NSPR	Marketable Securities Maturities Within One Year Fair Value MarketableSecuritiesMaturitiesWithinOneYearFairValue	17429000	usd
CY2023Q2	NSPR	Marketable Securities Maturities After One Through Two Years Fair Value MarketableSecuritiesMaturitiesAfterOneThroughTwoYearsFairValue	11388000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	28817000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	28838000	usd
	NSPR	Changes In Fair Value Of Marketable Securities ChangesInFairValueOfMarketableSecurities	-21000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	28817000	usd
CY2023Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	28817000	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	53449832	shares
CY2023Q2	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	155000000	shares
CY2023Q2	NSPR	Capital Stock Par Or Stated Value Per Share CapitalStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
	NSPR	Weighted Average Prefunded Warrants WeightedAveragePrefundedWarrants	3954956	shares
CY2023Q2	NSPR	Weighted Average Prefunded Warrants WeightedAveragePrefundedWarrants	7866452	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	75186979	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	75186979	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3010707	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3010707	shares
CY2023Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	303000	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	177000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	179000	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	513000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	510000	usd
CY2023Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	999000	usd
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	932000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1689000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1621000	usd
CY2023Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1263000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1853000	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	197000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	742000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	554000	usd
CY2023Q2	NSPR	Clinical Trial Accrual Current ClinicalTrialAccrualCurrent	1214000	usd
CY2022Q4	NSPR	Clinical Trial Accrual Current ClinicalTrialAccrualCurrent	1258000	usd
CY2023Q2	NSPR	Accrued Operating Lease Liabilities Current AccruedOperatingLeaseLiabilitiesCurrent	418000	usd
CY2022Q4	NSPR	Accrued Operating Lease Liabilities Current AccruedOperatingLeaseLiabilitiesCurrent	419000	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	121000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	130000	usd
CY2023Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	4061000	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	4411000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1649000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1531000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2888000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2714000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1649000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1531000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2888000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2714000	usd

Files In Submission

Name	View Source	Status
0001493152-23-027060-index-headers.html	Edgar Link	pending
0001493152-23-027060-index.html	Edgar Link	pending
0001493152-23-027060.txt	Edgar Link	pending
0001493152-23-027060-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nspr-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nspr-20230630_cal.xml	Edgar Link	unprocessable
nspr-20230630_lab.xml	Edgar Link	unprocessable
nspr-20230630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
nspr-20230630_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NSPR
InspireMD, Inc. Stock $nspr

2023 Q3 Form 10-Q Financial Statement

#000149315223027060 Filed on August 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NSPR InspireMD, Inc. Stock $nspr

2023 Q3 Form 10-Q Financial Statement

#000149315223027060 Filed on August 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NSPR
InspireMD, Inc. Stock $nspr